# Biospecimen Core

> **NIH NIH P50** · WEILL MEDICAL COLL OF CORNELL UNIV · 2021 · $129,259

## Abstract

BIOSPECIMEN CORE SUMMARY
The Biospecimen Core will provide collaborating investigators with both high-quality tissue samples (e.g.,
blood, urine, and surgical samples) and interpretative and consultative pathology services. Our over-arching
goal is to facilitate translational research through collection of highly annotated biological material and
associated clinical information. Thus, one of the major goals of this Core is to maintain and grow an existing
tissue, urine, and blood resource (henceforth referred to as the “Biobank”), which is linked to clinical outcome
data within a secure data management system that will be available to Weill Cornell Medicine (WCM) SPORE
in Prostate Cancer investigators as well as SPORE investigators at other institutions.
Currently, the biobanks of Weill Cornell Medicine (WCM) have enrolled more than 6,000 patients, with fresh
frozen tissue available for nearly 3,000 of these men. In addition to specimen collection, the Biospecimen Core
will deliver multiple routine and advanced pathology services to collaborating investigators by coordinating and
leveraging current Weill Cornell Medical College institutional resources. These services include histology,
immunohistochemistry, DNA and RNA in situ hybridization, computer assisted image analysis, laser-capture
micro-dissection, and the generation of and access to high-density tissue microarrays. Existing facilities and
services that will be provided through the Biospecimen and Pathology Core include the Translational Research
Program (TRP), the Englander Institute for Precision Medicine of WCM and New York-Presbyterian Hospital
(NYPH) including the next-generation sequencing (NGS) capabilities of the WCM Core lab. Juan Miguel
Mosquera, MD, and Brian Robinson, MD, as co-directors of the Biospecimen and Pathology Core, are
cognizant that first and foremost they are responsible for the optimal clinical care and protection of our
patients. Only after ensuring that sufficient information has been acquired to accurately grade and stage a
patient's tumor will samples be registered into the biobank. Further, the Biospecimen Core places patient
confidentiality and clinical care as a top priority. Patient confidentiality is guarded throughout the entire
process, from collection of patient material to their use in research projects. Patient advocates involved in the
SPORE program remind us of the importance of using these annotated samples for translational research to
reduce suffering from prostate cancer (PCa) as we consider this our mission.
!

## Key facts

- **NIH application ID:** 10227727
- **Project number:** 5P50CA211024-05
- **Recipient organization:** WEILL MEDICAL COLL OF CORNELL UNIV
- **Principal Investigator:** Juan Miguel Mosquera
- **Activity code:** P50 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $129,259
- **Award type:** 5
- **Project period:** 2017-08-30 → 2023-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10227727

## Citation

> US National Institutes of Health, RePORTER application 10227727, Biospecimen Core (5P50CA211024-05). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10227727. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*